TSG6 Antibody Research Receives a Nudge from Oncology Treatment Applications: Fact.MR

Rising burden of various types of cancers and the consequent increase in mortality rates is compelling clinicians to incorporate advanced diagnostics and treatment approaches, widening the scope for antibody treatment

Fact.MR Rockville: As the global burden of cancer increases, advanced therapeutic approaches are being investigated by key healthcare experts. This trend is likely to widen the berth for the TSG6 antibody market in forthcoming years. Award winning market research company Fact.MR is currently working on an exhaustive study concerning key application areas of TSG6 antibodies, with enhanced scope for future research across North America, Europe and the Asia-Pacific respectively.

According to the National Cancer Institute, an estimated 1.8 million new cancer cases were detected in the United States alone, with a perceived fatality rate of over 600,000 individuals. Prostate, lung and colorectal cancers accounted for nearly 43% of all cancers diagnosed in men as of 2020, with new rates averaging at 442.4 per 100,000 men and women annually. Consequently, healthcare providers are looking to leverage advanced therapeutic approaches, leading to extensive research and development.

Over the years, a host of manufacturers have dominated the TSG6 antibody landscape, offering different combinations aimed at streamlining oncology treatment. For instance, Biorbyt recently released the LYPLA3 antibody codenamed orb185108-Biotin, a rabbit-derived biotin antibody for applications across ELISA, ICC and IHC-P testing respectively. Similarly, Fitzgerald International manufactures primary antibodies, such as the Bradykinin Receptor Antibody and BT CRY2A Antibody.

“Accelerating research for discovering advanced therapeutic approaches to numerous chronic and infectious ailments is heightening scope for TSG6 antibody research, with manufacturers experimenting with different formulations to introduce novel treatment solutions,” remarks the Fact.MR analyst.

Request a report sample to gain comprehensive insights at


Key Takeaways from Fact.MR’s TSG6 Antibody Market Report

  • By product, above 95% TSG6 antibodies to experience high growth through the forecast period
  • Biopharmaceutical companies to remain primary TSG6 antibody end-users, owing to increasing clinical trials to fund advanced research
  • US to remain a potential market, with the FDA approving 79 therapeutic monoclonal antibodies as of 2019
  • Proliferating antibody research for chronic & infectious ailments to spearhead sales across the UK
  • Germany & France to experience high growth amid rising cancer research funding
  • Opportunities abound across the Asia-Pacific: China & India to emerge as key revenue ecosystems

TSG6 Antibody Market- Prominent Drivers

  • Rising cancer research initiatives for identifying tumor necrosis is expanding TSG6 antibody sales
  • The market is receiving traction amid rising demand across immunochemistry, western blotting and immunofluorescence
  • Clinicians are investigating additional application areas such as lung disorders treatment

TSG6 Antibody Market- Key Restraints

  • Shorter response to antibody therapy could lead to inaccurate conclusions, affecting the outcome
  • Perceived side effects such as anaphylaxis and low blood pressure to limit TSG6 antibody based treatments

Discover more about the TSG6 antibody market with figures, data tables and the table of contents. You will also find detailed market segmentation on https://www.factmr.com/report/2711/tsg6-antibody-market

Competitive Landscape

Key TSG6 antibodies providers profiled by Fact.MR include Thermo Fisher Scientific, Abbexa Ltd., Aviva Systems Biology Corporation, Boster Biological Technology, Genetex, Biorbyt, Fitzgerald Industries International, Lifespan Biosciences, Origene and US Biological among others. Primary expansion strategies include collaborations, acquisitions, research & development and new product launches.

In February 2021, Thermo Fisher Scientific successfully completed the acquisition of Mesa Biotech Inc., a privately held point-of-care molecular diagnostics company. The acquisition was carried out to acquire its Accula PCR-based testing system for infectious diseases. In the long-run, the acquisition is likely to also widen Thermo Fisher’s scope across chronic disease diagnostics, which will enhance its TSG6 antibody portfolio as well.

Boster Biological Technology is another prominent player, manufacturing the PicobandTM Anti-TSG6/TNFAIP6 Antibody, a rabbit-based IgG polyclonal antibody for tumor necrosis factor-inducible gene 6 protein detection. It consists of a synthetic peptide corresponding to a sequence at the N-terminus of human TSG6.

More Insights on the Global TSG6 Antibody Market

In its latest report, Fact.MR offers unbiased analysis of the globalTSG6 antibody market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of type (above 90%, above 95%, above 99% & others) and application (biopharmaceutical companies, hospitals, bioscience research institutions and others) across seven regions (North America, Latin America, Western Europe, Eastern Europe, Japan, APEJ and Middle East & Africa)

Get Customization on this Report for Specific Research Solutions


Explore Fact.MR’s Coverage on the Healthcare Domain

Benign Prostatic Hyperplasia Treatment Market: The study on the benign prostatic hyperplasia (BPH) treatment market is an exclusive report published by Fact.MR, which brings to the fore crucial parameters that have been influencing the growth of the market. This exclusive study provides incisive insights regarding recent developments in the benign prostatic hyperplasia treatment market, analyzing both historical as well as future data.

Asthma Treatment Market: The study on the asthma treatment market is an exclusive study, which has been recently added to the broad report repository of Fact.MR. The study brings to light crucial influencers that have been influencing the growth of the asthma treatment market. This comprehensive study offers analytical insights pertaining to the recent developments in the asthma treatment market.

Canes and Crutches Market: The study on the canes and crutches market is an exclusive report published by Fact.MR, which brings to the fore crucial parameters that are driving the growth of the market. This exclusive study provides incisive insights regarding recent developments in the canes and crutches market, by analyzing the historical as well as future data projections.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Sudip Saha
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Back to news